Evidence map›Paper›PMID 17306496›Full record

ArticleInternational journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience2007

A non-transformed oligodendrocyte precursor cell line, OL-1, facilitates studies of insulin-like growth factor-I signaling during oligodendrocyte development.

William H Lagarde, Robert Benjamin, Ann T Heerens, Ping Ye, Rick I Cohen, Billie M Moats-Staats, A Joseph D'Ercole

Abstract read
In one paragraph

Article in International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Frontiers in neuroscience · 2023
    Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

William H LagardeDepartment of Pediatrics, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7039, USA. Bill_Lagarde@med.unc.edu
Robert Benjamin
Ann T Heerens
Ping Ye
Rick I Cohen
Billie M Moats-Staats
A Joseph D'Ercole
University of North Carolina at Chapel Hill · USCoriell Institute For Medical Research · US

Funding

INSULIN LIKE GROWTH FACTOR 1 ACTIONS IN OLIGODENDROCYTER01NS038891 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI D'ERCOLE, AUGUSTINE JOSEPH · 1999 to 2007
$2.2M
Mechanism of IGF-I actions on oligodendroglial cellsR01NS048868 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI D'ERCOLE, AUGUSTINE JOSEPH · 2004 to 2008
$1.7M
NINDS NIH HHS NS038891NINDS NIH HHS NS048868NINDS NIH HHS R01 NS038891NINDS NIH HHS R01 NS048868
6 · The paper itself

Abstract

The process by which oligodendrocyte progenitors differentiate into mature oligodendrocytes is complex and incompletely understood in part because of the paucity of oligodendrocyte precursors cell lines that can be studied in culture. We have developed a non-immortalized rat oligodendrocyte precursor line, called OL-1, which behaves in a fashion consistent with developing oligodendrocytes in vivo. This OL-1 line provides a model for the study of oligodendrocyte development and offers an alternative to the CG-4 cell line. When OL-1 cells are propagated in conditioned growth media, they have morphology consistent with immature oligodendrocytes and exhibit A2B5 antigen positive and myelin basic protein-negative immunoreactivity. Withdrawal of conditioned growth media and culture in serum-free medium results in OL-1 cell maturation, manifested by a shift to myelin basic protein-positive immunoreactivity, A2B5 antigen-negative immunoreactivity, decreased NG2 mRNA expression, increased expression of proteolipid protein mRNA, and increased expression of CNP protein. In addition, the expression of proteolipid protein and its splicing variant DM-20 exhibit a pattern that is similar to brain proteolipid protein expression during development. When OL-1 cells are exposed to Insulin-like growth factor-I, there are significant increases in proteolipid protein mRNA expression (p<0.05), the number of cell processes (p<0.05), and cell number (p<0.05). Treatment with the caspase inhibitors Z-DEVD-FMK and Z-VAD-FMK (inhibitors of caspases 3, 6, 7, 8, 10 and 1, 3, 4, respectively), Insulin-like growth factor-I, or both, results in a similar increase in cell number. Because Insulin-like growth factor-I does not substantially increase the BrdU labeling of OL-1 cells, these data collectively indicate that Insulin-like growth factor-I increases OL-1 cell number predominately by promoting survival, rather than stimulating proliferation. This non-immortalized oligodendrocyte precursor cell line, therefore, exhibits behavior consistent with the in vivo development of oligodendrocytes and provides an excellent model for the study of developing oligodendrocytes.

Indexed as

AnimalsAnimals, NewbornAntigensAntigens, SurfaceCaspase InhibitorsCaspasesCell CountCell DifferentiationCell LineCells, CulturedCell ShapeCell SurvivalCentral Nervous SystemChondroitin Sulfate Proteoglycan 4Culture Media, ConditionedEnzyme InhibitorsAntigensAntigens, Surfaceatrial natriuretic factor receptor CCaspase InhibitorsCaspasesChondroitin Sulfate Proteoglycan 4Culture Media, ConditionedEnzyme InhibitorsInsulin-Like Growth Factor IMyelin Basic ProteinMyelin Proteolipid ProteinProteoglycansReceptors, Atrial Natriuretic FactorRNA, Messenger

Identifiers

PMID17306496
PMCPMC2302791
OpenAlexW2020039121

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.